Weight LossLegally CompoundedFDA Approved

Tirzepatide

About

About Tirzepatide

A synthetic dual agonist peptide, tirzepatide activates both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors to enhance insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite. The compound produces significant improvements in glycemic control and body weight reduction. Primary clinical applications include treatment of type 2 diabetes mellitus and chronic weight management in adults with obesity.

Science

Mechanism of Action

Tirzepatide is a dual GIP/GLP-1 receptor agonist. GLP-1R activation suppresses appetite, stimulates glucose-dependent insulin secretion, slows gastric emptying, and reduces glucagon. GIP receptor activation enhances insulin secretion synergistically, improves adipose tissue lipid metabolism, and may modulate central appetite regulation. The combination produces greater weight loss and metabolic improvement than GLP-1 agonism alone.

Dosing

Typical Protocol

Week 1–4: 2.5 mg subcutaneously once weekly. Week 5–8: 5 mg once weekly. Ongoing titration: increase by 2.5 mg every 4 weeks as tolerated, up to 15 mg/week. Maintenance: 10–15 mg once weekly for maximum efficacy. Contraindications mirror semaglutide: MEN2, medullary thyroid carcinoma, pancreatitis.

⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.

Regulatory

Legal Status in 2026

Legally Compounded

This compound is legal to prescribe and dispense through a licensed 503A or 503B compounding pharmacy with a valid prescription. It is not FDA-approved as a finished drug product, but compounding is explicitly permitted under federal law. Quality and sterility standards vary by pharmacy — look for PCAB-accredited compounders.

Evidence

Evidence Tier

FDA Approved

Supported by the clinical trial data required for FDA approval, representing the highest evidence bar. Safety and efficacy have been established in multiple phases of human clinical trials.